PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
547.73%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
547.73%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
3.95%
Interest expense growth 0-5% reflects moderate increase. Benjamin Graham would check leverage ratios.
-96.03%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-2633.53%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
-429.59%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-263.73%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-197.18%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
22.83%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
22.83%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.